Cargando…

Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma

Detalles Bibliográficos
Autores principales:	Shimose, Shigeo, Koya, Shunji, Kawaguchi, Takumi, Hirota, Keisuke, Yoshio, Sachiyo, Niizeki, Takashi, Matsuse, Hiroo, Torimura, Takuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524069/ https://www.ncbi.nlm.nih.gov/pubmed/34517441 http://dx.doi.org/10.3350/cmh.2021.0258

Ejemplares similares

Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma
por: Kawaguchi, Takumi, et al.
Publicado: (2020)

Effects of In-Hospital Exercise on Frailty in Patients with Hepatocellular Carcinoma
por: Tsuchihashi, Jin, et al.
Publicado: (2021)

Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma
por: Kamachi, Naoki, et al.
Publicado: (2021)

Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma
por: Hashida, Ryuki, et al.
Publicado: (2020)

Profiles Combining Muscle Atrophy and Neutrophil-to-Lymphocyte Ratio Are Associated with Prognosis of Patients with Stage IV Gastric Cancer
por: Shigeto, Kota, et al.
Publicado: (2020)

Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching
por: Shimose, Shigeo, et al.
Publicado: (2023)

A low‐intensity 10‐min resistance exercise program that ameliorated hepatic fibrosis indices and altered G‐CSF/IP‐10/PDGF‐BB in a patient with nonalcoholic fatty liver disease: A case report
por: Hashida, Ryuki, et al.
Publicado: (2023)

Association between contrast enhancement on contrast-enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma
por: Okamura, Shusuke, et al.
Publicado: (2022)

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2020)

Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
por: Shimose, Shigeo, et al.
Publicado: (2020)

Effects of In-Hospital Physical Therapy on Activities of Daily Living in Patients with Hepatocellular Carcinoma
por: Narao, Hayato, et al.
Publicado: (2020)

Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound
por: Kamachi, Naoki, et al.
Publicado: (2021)

Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study
por: Shimose, Shigeo, et al.
Publicado: (2020)

Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study
por: Shimose, Shigeo, et al.
Publicado: (2021)

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Iwamoto, Hideki, et al.
Publicado: (2022)

Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
por: Shimose, Shigeo, et al.
Publicado: (2020)

Changes in prognostic factors for patients with hepatocellular carcinoma underwent transarterial chemoembolization with the transition of the time: Child-Pugh class, Albumin-Bilirubin grade, and then
por: Kawaguchi, Takumi, et al.
Publicado: (2020)

Valine, a Branched-Chain Amino Acid, Reduced HCV Viral Load and Led to Eradication of HCV by Interferon Therapy in a Decompensated Cirrhotic Patient
por: Kawaguchi, Takumi, et al.
Publicado: (2012)

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
por: Iwamoto, Hideki, et al.
Publicado: (2023)

Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events
por: Iwamoto, Hideki, et al.
Publicado: (2020)

Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis
por: Shirono, Tomotake, et al.
Publicado: (2021)

Effects of SGLT2 inhibitor on tumor‐releasing chemokines/cytokines in Hep3B and Huh7 cells
por: Nakano, Dan, et al.
Publicado: (2022)

Association between Activity and Brain-Derived Neurotrophic Factor in Patients with Non-Alcoholic Fatty Liver Disease: A Data-Mining Analysis
por: Hashida, Ryuki, et al.
Publicado: (2021)

Primary Treatment with Molecular‐Targeted Agents for Hepatocellular Carcinoma: A Propensity Score‐matching Analysis
por: Nakano, Masahito, et al.
Publicado: (2020)

Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis
por: Kawaguchi, Takumi, et al.
Publicado: (2022)

Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2016)

Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion
por: Niizeki, Takashi, et al.
Publicado: (2021)

Usefulness of a novel transarterial chemoinfusion plus external‐beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study
por: Shirono, Tomotake, et al.
Publicado: (2021)

Total and High Molecular Weight Adiponectin and Hepatocellular Carcinoma with HCV Infection
por: Sumie, Shuji, et al.
Publicado: (2011)

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2022)

Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2015)

Durable complete response is achieved by balloon‐occluded transcatheter arterial chemoembolization for hepatocellular carcinoma
por: Shirono, Tomotake, et al.
Publicado: (2022)

Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2022)

The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function
por: Iwamoto, Hideki, et al.
Publicado: (2022)

Effects of isomaltulose on insulin resistance and metabolites in patients with non-alcoholic fatty liver disease: A metabolomic analysis
por: Kawaguchi, Takumi, et al.
Publicado: (2018)

Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments
por: Suzuki, Hiroyuki, et al.
Publicado: (2021)

Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review
por: Suzuki, Hiroyuki, et al.
Publicado: (2022)

The effects of branch-chain amino acids on fatigue in the athletes
por: Vahid, Imanipour, et al.
Publicado: (2018)

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
por: Sano, Tomoya, et al.
Publicado: (2021)

Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma
por: Nakano, M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2ojjm56jds1qelb68fg3dvi572